OBJECTIVE: The results concerning therapeutic drug monitoring of Quetiapin concentration in 152 in-patients will be presented. METHOD: In addition to measuring the serum concentration of Quetiapin standardized patient data were collected and the clinical history assessed by the Brief Psychiatric Rating Scale (BPRS). RESULTS: A significant positive correlation of the serum concentration and the daily dosage was found. Co-medication with the CYP 3A4 inhibitor Nefazodon was associated with an increase in the serum concentration without any adverse interactions occurring. CONCLUSION: While a correlation of dosage and effect could be shown with Quetiapin, inter- and intraindividual differences could be observed. Drug monitoring therefore seems useful in clinical setting and is recommended.
OBJECTIVE: The results concerning therapeutic drug monitoring of Quetiapin concentration in 152 in-patients will be presented. METHOD: In addition to measuring the serum concentration of Quetiapin standardized patient data were collected and the clinical history assessed by the Brief Psychiatric Rating Scale (BPRS). RESULTS: A significant positive correlation of the serum concentration and the daily dosage was found. Co-medication with the CYP 3A4 inhibitor Nefazodon was associated with an increase in the serum concentration without any adverse interactions occurring. CONCLUSION: While a correlation of dosage and effect could be shown with Quetiapin, inter- and intraindividual differences could be observed. Drug monitoring therefore seems useful in clinical setting and is recommended.
Authors: Michael A Cerullo; Allison A Albertz; Jennifer N Bell; Robert M Anthenelli; Melissa P Delbello Journal: Am J Psychiatry Date: 2008-07 Impact factor: 18.112